Neuraly, Inc. is a biotechnology company founded with the mission to develop revolutionary treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. The company focuses on creating neuro-protective therapies that target new pathways, leveraging innovative scientific research to deliver medicines with the potential to significantly improve patient outcomes. Based in Maryland, Neuraly aims to offer new hope to those affected by progressive neurological disorders through its cutting-edge drug development.

Key figures associated with Neuraly include its founders, whose innovations form the backbone of the company's scientific platform. The company has garnered attention and investment from notable investors in the biotech sector, underscoring its potential impact. Neuraly's achievements include advancing its drug candidates through critical stages of development, positioning itself as a promising player in the fight against debilitating neurodegenerative diseases. Through its pioneering work, Neuraly is making significant strides in transforming the treatment landscape for these conditions.